このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Rigel Pharmaceuticals マネジメント

マネジメント基準チェック /24

Rigel Pharmaceuticals'の CEO はRaul Rodriguezで、 May2010年に任命され、の在任期間は 14.08年です。の年間総報酬は$ 3.44Mで、 21.2%給与と78.8%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.75%を直接所有しており、その価値は$ 1.22M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と6.6年です。

主要情報

Raul Rodriguez

最高経営責任者

US$3.4m

報酬総額

CEO給与比率	21.2%
CEO在任期間	14.1yrs
CEOの所有権	0.7%
経営陣の平均在職期間	3.1yrs
取締役会の平均在任期間	6.6yrs

経営陣の近況

Recent updates

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

Feb 01

An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Jan 14

Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive

Nov 30

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Nov 02

Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines

Sep 06

CEO報酬分析

Rigel Pharmaceuticals の収益と比較して、Raul Rodriguez の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$3m	US$728k	-US$25m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$700k	-US$59m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	US$3m	US$662k	-US$18m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$3m	US$662k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$3m	US$649k	-US$67m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$59m
Mar 31 2019	n/a	n/a	-US$64m
Dec 31 2018	US$4m	US$637k	-US$70m
Sep 30 2018	n/a	n/a	-US$100m
Jun 30 2018	n/a	n/a	-US$93m
Mar 31 2018	n/a	n/a	-US$87m
Dec 31 2017	US$2m	US$618k	-US$78m

報酬と市場: Raulの総報酬 ($USD 3.44M ) は、 US市場 ($USD 1.58M ) の同規模の企業の平均を上回っています。

報酬と収益: Raulの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Raul Rodriguez (63 yo)

14.1yrs

在職期間

US$3,440,790

報酬

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Raul Rodriguez	President	14.1yrs	US$3.44m	0.75% $ 1.3m
Dean Schorno	Executive VP & CFO	6.1yrs	US$1.21m	0.069% $ 116.3k
Raymond Furey	Executive VP	1.5yrs	US$683.00k	0.0029% $ 4.8k
David Santos	Executive VP & Chief Commercial Officer	3.8yrs	US$1.34m	0.031% $ 52.7k
Julie Patel	Senior VP of Human Resources	2.4yrs	データなし	データなし
Esteban Masuda	Executive Vice President of Research	7.8yrs	US$796.09k	データなし
Joseph Lasaga	Executive VP & Chief Business Officer	less than a year	データなし	データなし
Lisa Rojkjaer	Executive VP & Chief Medical Officer	less than a year	データなし	データなし
Tarek Sallam	Vice President of Marketing	no data	データなし	データなし

3.1yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: RIGLの経営陣は経験豊富であると考えられます ( 3.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Raul Rodriguez	President	9.6yrs	US$3.44m	0.75% $ 1.3m
Walter Moos	Independent Director	27.3yrs	US$138.58k	0.044% $ 73.8k
Brian Kotzin	Independent Director	6.8yrs	US$138.58k	0.043% $ 71.7k
Jane Wasman	Independent Director	5.3yrs	US$145.58k	0.043% $ 71.7k
Gregory Lapointe	Independent Chairman of the Board	6.6yrs	US$190.58k	0.043% $ 71.7k
Kamil Ali-Jackson	Independent Director	2.5yrs	US$140.58k	0.025% $ 41.8k
Alison Hannah	Independent Director	3.1yrs	US$212.98k	0.032% $ 53.8k

6.6yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: RIGLの取締役会は経験豊富であると考えられます ( 6.6年の平均在任期間)。

Rigel Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

President recently sold US$60k worth of stock

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

President recently bought US$688k worth of stock

Recent updates

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients

Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Now 22% undervalued after recent price drop

Rigel Pharmaceuticals, Inc. Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Now 21% undervalued

Price target decreased to US$2.08

Rigel Pharma adds ~7% to reach over two month high

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rigel rises 17% on strong Q2 result

Rigel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022

President recently bought US$688k worth of stock

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Forward Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

Rigel Pharmaceuticals: A Status Check

Consensus forecasts updated

No longer forecast to breakeven

マネジメント基準チェック /24